文献速递妇科

经皮射频消融治疗腹壁子宫内膜异位症的可行性:一项前瞻性先导研究

Feasibility of Percutaneous Radiofrequency Ablation for Abdominal Wall Endometriosis: A Prospective Pilot Study.
PubMed 文献 · J Minim Invasive Gynecol · 2024-10-26

该介入性、前瞻性、非对照1期临床试验在里昂Croix Rousse大学医院多学科子宫内膜异位症专家中心纳入10例患者(12个腹壁子宫内膜异位症病灶),评估超声引导下经皮射频消融的可行性及其对症状和病灶体积的疗效。结果显示100%可行性,6个月时9例(90%)触诊结节疼痛消失,周期性疼痛视觉模拟评分显著下降,非周期性疼痛显著下降,生活质量SF36总分显著提高,磁共振成像示结节体积显著缩小78%,11/12个病灶无血管化/强化,报告1例严重不良事件(切口疝)。结论认为经皮射频消融可行,可能为腹壁子宫内膜异位症的一种临床有效治疗。

要点

  • 10例患者12个腹壁子宫内膜异位症病灶经皮射频消融,可行性为100%。
  • 6个月时9例(90%)触诊结节疼痛消失,周期性及非周期性疼痛评分均显著下降。
  • 6个月时磁共振成像示结节体积显著缩小78%,11/12个病灶无血管化/强化。

核心结论

  • 经皮射频消融可行,可能为腹壁子宫内膜异位症的一种临床有效治疗。

研究设计与样本

  • 介入性、前瞻性、非对照1期临床试验,在里昂Croix Rousse大学医院多学科子宫内膜异位症专家中心进行。
  • 纳入10例有1至3个腹壁子宫内膜异位症病灶的患者,接受经皮射频消融并随访6个月。

主要发现

  • 2020年6月25日至2022年7月27日共治疗10例患者(12个结节),8例在局部麻醉下、2例在全身麻醉下进行,可行性为100%。
  • 9例有既往剖宫产史。
  • 6个月时触诊结节疼痛在9例(90%)中消失。
  • 6个月时周期性疼痛视觉模拟评分从5.7分(标准差0.9)显著降至0.9分(标准差3.2),P=0.03;非周期性疼痛从3.8分(标准差0.8)显著降至1.3分(标准差3.3),P=0.02。
  • 6个月时生活质量SF36总分显著提高218分,P<0.01;磁共振成像示结节体积显著缩小78%(1.2 cm³,标准差1.3 vs 5.4 cm³,标准差8.2,P<0.01),11/12个治疗结节在术后磁共振成像上无血管化/强化。

临床怎么用

  • 原文结论认为经皮射频消融可行,可能为腹壁子宫内膜异位症的一种临床有效治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY OBJECTIVE: To assess the feasibility of percutaneous radiofrequency ablation (PRFA) of anterior abdominal wall endometriosis (AWE) lesions and to describe its efficacy on clinical symptoms and on the volume of the lesion. DESIGN: Interventional, prospective, noncomparative, phase 1 clinical trial. SETTING: Patients consulting at the multidisciplinary endometriosis expert center at Croix Rousse University Hospital (Hospices Civils de Lyon). PATIENTS: Ten patients with 1 to 3 AWE lesions treated by PRFA with 6 months follow-up. INTERVENTIONS: PRFA of AWE lesions were performed under ultrasound guidance. Initial power ranged from 3 to 10 W, with progressive increases in power. The thermal effect in the ablation zone was monitored in real-time (appearance of hyperechoic signals). A contrast-enhanced ultrasound check was also carried out. We used multiShot technique until the entire nodule was covered by the hyperechogenic cloud. MEASUREMENTS AND MAIN RESULTS: Ten patients (12 nodules) were positively treated from June 25, 2020 to July 27, 2022, 8 under local anesthesia and 2 under general anesthesia, which represented 100% feasibility. Nine patients had previous cesarean section. At 6 months, the nodule pain at palpation disappeared for 9 patients (90%), mean cyclic pain visual analogic scale significantly decreased from 5.7 points (0.9 SD 0.9 vs 6.6 SD 3.2 p = .03) and noncyclic pain from 3.8 points (0.8 SD 1.3 vs 4.6 SD 3.3 p = .02). Patients reported a significant improvement of their quality of life at 6 months (SF36 total score increase by 218 points p <.01). We observed a significant reduction of 78% in the volume of the nodule at 6 months on magnetic resonance imaging (1.2 cm3 SD 1.3 vs 5.4 cm3 SD 8.2 p <.01); 11/12 treated nodules were nonvascularized/enhanced on postprocedure magnetic resonance imaging. All Patients were treated on an outpatient basis. We report one severe adverse event (incisional hernia). CONCLUSION: PRFA is feasible and may be a clinically effective treatment for AWE.

来源:J Minim Invasive Gynecol,查看原文。版权归原作者所有。

引用

  1. Haquin A, Delacroix C, Rode A, et al. Feasibility of Percutaneous Radiofrequency Ablation for Abdominal Wall Endometriosis: A Prospective Pilot Study. J Minim Invasive Gynecol. 2024. PMID: 39490892. doi:10.1016/j.jmig.2024.10.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。